Imagion Biosystems addresses late ASX filing on convertible note repayment

Imagion Biosystems Ltd. ( (AU:IBX) ) has provided an update.

Imagion Biosystems has advised that it recently lodged an Appendix 3H with the ASX relating to the part repayment of convertible notes held by Mercer Street Global Opportunity Fund, after the filing was submitted later than required due to an administrative oversight. The company noted that the underlying $300,000 part repayment of previously issued convertible notes had already been disclosed in January 2026 and said it has reviewed internal processes to strengthen compliance with continuous disclosure and ASX Listing Rules, aiming to reassure investors about its governance and reporting practices.

The board-authorised announcement underscores Imagion’s efforts to maintain transparent communication with the market while it continues advancing its MagSense imaging technology in oncology. The company also invited shareholders and potential investors to engage via its Investor Hub platform, signaling an ongoing focus on investor relations alongside its clinical and commercial development activities.

The most recent analyst rating on (AU:IBX) stock is a Sell with a A$0.02 price target. To see the full list of analyst forecasts on Imagion Biosystems Ltd. stock, see the AU:IBX Stock Forecast page.

More about Imagion Biosystems Ltd.

Imagion Biosystems Limited is a clinical-stage medical imaging company focused on transforming cancer diagnosis and treatment. The company has developed MagSense, a first-of-its-kind MRI imaging agent that uses non-radioactive, bio-safe magnetic nanoparticles to improve early detection and diagnostic precision across cancers such as HER2-positive breast, prostate, and ovarian cancers.

Average Trading Volume: 2,348,109

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$10.3M

For an in-depth examination of IBX stock, go to TipRanks’ Overview page.